Reuters
- Shares of Sorrento Therapeutics spiked as much as 244% on Friday after the company said an antibody it was developing showed "100% inhibition" of the COVID-19 virus in preclinical studies.
- The small biotechnology company said it aimed to create "an antibody cocktail that would act as a 'protective shield'" against the coronavirus.
- Sorrento said the full results of from its experiments would be "submitted to a peer-reviewed publication shortly."
- Visit Business Insider's homepage for more stories.
Sorrento Therapeutics skyrocketed as much as 244% on Friday after the company said an antibody it was developing showed "100% inhibition" of the COVID-19 virus in preclinical studies.
The small biotechnology company said it planned to "generate an antibody cocktail product that would act as a 'protective shield' against SARS-CoV-2," the official name of the novel coronavirus.
See the rest of the story at Business Insider
NOW WATCH: What makes 'Parasite' so shocking is the twist that happens in a 10-minute sequence
See Also:
- 10 big money managers shared with us their favorite hidden gems in the market, and the contrarian trades they're making amid the pandemic
- Todd Ahlsten has dominated the market and his competitors for 2 decades. He lays out the 6 stock-picking decisions that reshaped his portfolio after the coronavirus meltdown.
- Goldman Sachs slashes forecasts, now sees GDP shrinking 39% this quarter and unemployment at 25%
from Business Insider https://ift.tt/2LCteDb
No comments:
Post a Comment